anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There have been postmarketing reports of acute pancreatitis in patients taking saxagliptin. In a cardiovascular outcomes trial enrolling participants with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (SAVOR trial), cases of definite acute pancreatitis were confirmed in 17 of 8240 (0.2%) patients receiving saxagliptin compared to 9 of 8173 (0.1%) receiving placebo. Pre-existing risk factors for pancreatitis were identified in 88% (15/17) of those patients receiving saxagliptin and in 100% (9/9) of those patients receiving placebo.

After initiation of QTERN, observe patients for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue QTERN and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using QTERN.
Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. (1) Within this population, AF is considered to be multifactorial in origin (2) but associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. (3,4) Multiple interventions have been tried before including anti-arrhythmic drugs (amiodaron, verapamil, sotalol) and rate reducing agents like beta-blockers. (5-7) Although encouraging results have been found with different regimes, adaptation in clinical practice has been hampered by toxicity (amiodarone) and therapeutic index. Magnesium has been identified as a potentially interesting compound with easy access and low toxicity; besides, hypomagnesemia has been observed frequently immediately after cardiac surgery. (8,9) Both reduction of abnormal activity of atrial myocardium and prolongation of the atrial refractory period caused by administration of magnesium may prevent AF. (10) Magnesium metabolism has identified that less then 1% of the total magnesium content is intravascular and serum levels don't always correlate with intracellular concentrations. (11) Hypomagnesaemia is associated with increased ventricular tachycardia and atrial fibrillation which is likely caused by a reduction in membrane triphosphate (ATP) activity. This results in reduced membrane stabilization due to a reduction in intracellular potassium compared to extracellular concentrations thus increasing electrical excitability. (12) Also measuring the intracellular concentration is difficult and especially in a routine fashion as loading tests followed by 24 hour urine analysis (13) and energy-dispersive X-ray analysis are not available. (14) Administration of magnesium sulphate does however correlate to higher intracellular magnesium concentration compared to placebo. (14) Several studies in different populations have shown a reduction in arrhythmias post magnesium supplementation. (15) Previous studies suggest that magnesium administration after cardiac surgery is effective in reducing the incidence of AF. (16) However, uncertainty remains regarding optimal dose/blood levels, duration and method of magnesium administration. (17) In a recent study using a protocol for administration of magnesium aiming for blood levels between 1.5 and 2.0 mmol/L an absolute reduction of POAF of 15.1% (OR 0.49, 95% CI 0.27-0.92) was demonstrated. (18) Based on this study, we designed the POMPAE trial (Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated). The POMPAE trial is a double blinded randomized clinical trial to investigate the efficacy of magnesium supplementation and the reduction of POAF.
R115777, 300mg PO BID on Days 1-21. 1 cycle=28 days.
Many analgesic options exist for laboring parturients, but labor may not be the best time to start informing patients of their options. Many patients begin the labor process with a plan in place for their analgesia. Unfortunately, internet resources regarding labor analgesia that are available to the lay parturient are poor and often lead to misconceptions about the options and their risks. A significant number of patients refuse neuraxial analgesia based on misunderstandings, concerns about the procedure, or a lack of faith in the provider. Some women want a "natural childbirth" and/or control over their labor experience. Our study aimed at providing information and alternatives for labor analgesia in a simple written format.

The investigators will provide information of available labor analgesia options (epidural, combined spinal/epidural, spinal, remifentanil patient-controlled analgesia, and intravenous opioids) to expecting mothers. Using a pamphlet written in English or Spanish disseminated to pregnant women in clinic and upon arrival in the labor and delivery unit, the procedures and their risks and benefits will be explained in simple terms. In the Labor and Delivery Unit the patients will have an opportunity to ask questions of the anesthesia care giver regarding the options for analgesia. After delivery while on F Green, patients will be asked to complete a questionnaire addressing their thoughts about the pamphlets and their overall satisfaction with their labor analgesia. The analysis will focus on the utility and effect of education materials on maternal informed consent for labor analgesia, on maternal choice of analgesia modality, and on maternal anxiety regarding their labor analgesia plan.
The invention relates to the technical field of nano drug delivery systems, in particular to a carbonized MOFs nanoparticle carrying phagocytic peptide, a preparation method and application thereof in imaging and treating retinoblastoma. A phagocytosis peptide-loaded carbonized MOFs nanoparticle comprising a carbonized metal-organic framework compound loaded with a phagocytosis peptide. The nano particles of the scheme have PA/MR bimodal imaging capability and good photo-thermal/immune treatment effect. The nano particles have good in-vivo and in-vitro biological safety, and stable magnetism enables the nano particles to have magnetic targeting capability, and can deliver the phagocytic peptide to a tumor area, so that the photothermal/immunotherapy effect of the tumor is improved, and the tumor is effectively inhibited. By enhancing the PA/MR imaging and inhibiting the tumor growth, the nano particles have great potential in the aspect of bimodal imaging-guided photo-thermal/immune cooperative therapy (RB), and provide a foundation for the diagnosis and treatment integration of the RB. Has ideal application prospect.
Participants will be instructed to follow their usual diet and lifestyle. Participants will be allowed to consume up to 2 avocados per month, but avocado consumption will not be encouraged and no avocados will be provided. Compliance visits will be conducted monthly.
The present invention relates to developmental disorder diagnosis and treatment. More particularly, the present invention relates to a method and a system for terminal-based developmental disorder diagnosis and treatment by a virtual therapist. According to the present invention, a user's face, age, gender, emotion, and motion are recognized, mutual sympathy is performed between the virtual therapist and a person with a developmental disorder, and thus the developmental disorder can be improved. According to the present invention, the virtual therapist is displayed on a terminal display, a user's face, age, and gender are recognized with a camera, and the virtual therapist develops a conversation with the user to perform developmental disorder diagnosis. At this time, the user is caused to touch the display, make an utterance, or follow a certain behavior. Then, the user's language development stage is derived and the virtual therapist develops developmental disorder treatment suitable for the current language development stage.
Investigators will select the first drug listed in the tumor analysis report for the first mutation listed in the tumor analysis report. However, If the subject has a medical contraindication to the first listed drug (according to the drug label) or the first listed drug cannot be obtained for the patient, the study team will select the next drug presented by the tumor sequencing report. Patients receive targeted therapy based on next generation sequencing report. Cycles repeat every 2, 4, or 6 weeks in the absence of disease progression or unacceptable toxicity.
Multiple sclerosis (MS) is a progressive disease of the central nervous system characterized by demyelination and destruction of motor and sensory axons. As the disease worsens, it is associated with impaired balance, difficulty walking, decreased mobility, and an increased risk of falling. The prevalence of balance dysfunction in individuals with MS and Given its clinical relevance, the assessment of balance has become an important focus in MS clinical practice and research.The Four Square Step Test is a standard clinical measure used to assess dynamic standing balance.The individual rapidly forwards over a low obstacle (a cane), is a timed test in which instructed to step backward and to the right and left.The four-frame stepping test was developed to document deficiencies in stance balance, predict falls, assess self-perceived limitations in walking, and compare changes in standing balance following exercise training. Compared to other standardized tests, scoring is not dependent on the subjectivity of the examiner, can be administered by a person with minimal training, and requires minimal time, space, and equipment. In the modified four-square stepping test, the floor is divided into four equal squares with tape instead of a cane. Performing the test with tape, instead of patients at risk of being stuck with a cane, will ensure its applicability to a wider patient population.
PURPOSE:The titled lowering agent comprising pine nut or a pine nut oil of naturally occurring substance as a main component. CONSTITUTION:A pine nut oil is obtained from fine nuts (e.g., edible pine nuts of Pinus Koraiensis, Pinus Sibirica, Pinus Cembraides, etc.) by pressing method, solvent extraction method, supercritical gas extraction method to give a purified pine nut oil. An agent for lowering cholesterol comprising pine nut or a pine nut oil [containing preferably >=10wt% 5,9,12-cis-octadecatrienoic acid (ODT acid) or its derivative] as main component, containing ODT acid or its derivative. The purified pine nut oil contains 40-50wt% linoleic acid and 15-19wt% ODT acid in constituent fatty acids and can be used directly as it is. In administration, the agent may be added to a food directly as it is or may be processed into tablets or capsules and administered. EFFECT:The titled agent has no side effects, pine nuts of raw material are relatively easily obtainable and the agent is industrially advantageous.
FIELD: cosmetology. ^ SUBSTANCE: invention is related to cosmetic industry, in particular to composition for moistening of skin, hair and/or nails. Composition for moistening of skin, hair and/or nails, including maleate of castor oil, hydrolysed keratin from goat's hair, surface-active alkylsulfate of ether, surface-active cocamidopropyl betaine and other components taken in a certain amount. Method for moistening of skin, hair and/or nails, including application of efficient number of above described composition onto skin, hair and/or nails. Application of above described composition for application of substance selected from odorants, solar protection facility, pigments, repellents for insects and/or waterproof substances, onto skin, hair and/or nails, where specified substance is included into composition of above mentioned substance, and composition is applied onto skin, hair and/or nails. ^ EFFECT: above described composition efficiently moisturises skin, hair and/or nails. ^ 12 cl, 4 tbl, 4 ex
This study develops a couple-based HIV prevention intervention that is innovative and important because it integrates an intervention that improves sexual health, relationship functioning, and parenting skills. Our intervention will be integrated with an existing community based parenting program. By targeting high risk heterosexual couples experiencing an important life transition that increases their stress, conflict, and sexual risk, the investigators can provide maximum benefit to the men, women, and children in our communities. Using the guiding framework of Attachment Theory and the principles of Emotion Focused Therapy, the investigators will directly address issues of emotion, intimacy,and relationship functioning to create an intervention that strengthens romantic relationships and reduces HIV risk behavior. The investigators will conduct a small pilot randomized controlled trial of 50 parenting couples randomized to either the relationship strengthening HIV prevention intervention or an active control. The intervention will last 15 weeks and each session will be approximately 1.5 hours long. The investigators will assess couples at baseline, 4-months, and 8-months.
BACKGROUND: Seizures are reported to be more prevalent in individuals with multiple sclerosis (MS) compared with the general population. Existing data predominantly originate from population-based studies, which introduce variability in methodologies and are vulnerable to selection and reporting biases.
METHODS: This meta-analysis aims to assess the incidence of seizures in patients participating in randomised clinical trials and to identify potential contributing factors. Data were extracted from 60 articles published from 1993 to 2022. The pooled effect size, representing the incidence rate of seizure events, was estimated using a random-effect model. Metaregression was employed to explore factors influencing the pooled effect size.
RESULTS: The meta-analysis included data from 53 535 patients and 120 seizure events in a median follow-up of 2 years. The pooled incidence rate of seizures was 68.0 per 100 000 patient-years, significantly higher than the general population rate of 34.6. Generalised tonic-clonic seizures were the most common type reported, although there was a high risk of misclassification for focal seizures with secondary generalisation. Disease progression, longer disease duration, higher disability levels and lower brain volume were associated with a higher incidence of seizures. Particularly, sphingosine-1-phosphate receptor (S1PR) modulators exhibited a 2.45-fold increased risk of seizures compared with placebo or comparators, with a risk difference of 20.5 events per 100 000 patient-years.
CONCLUSIONS: Patients with MS face a nearly twofold higher seizure risk compared with the general population. This risk appears to be associated not only with disease burden but also with S1PR modulators. Our findings underscore epilepsy as a significant comorbidity in MS and emphasise the necessity for further research into its triggers, preventive measures and treatment strategies.
Three consecutive days for 20 minutes daily of neutral writing. Different topics of own knowledge Description of the city, their room, their place where they live, or easy procedure like, how to make a coffee (or something else), their population, trying to remain free from deep emotions, thoughts, or feelings.
PURPOSE:To obtain the subject readily usable and concentrated composition having extremely strong activity by roasting and fermenting plant seeds, preparing a composition therefrom, washing the resultant composition with a nonpolar solvent and then extracting the washed composition with a polar solvent. CONSTITUTION:Plant seeds and/or embryo buds are roasted and a microorganism is then added thereto and fermented while being sufficiently stirred to liberate and produce a large amount of a low-molecular anti-active oxygen substance. After completing the fermentation, the plant seeds are added to afford an anti-active oxygen action composition. The resultant composition is then washed with a nonpolar solvent such as benzene, n-hexane or ether to remove coloring matters, fat-soluble substances, etc., without any anti-active oxygen action in the aforementioned composition. Ingredients insoluble in the nonpolar solvent are subsequently extracted with a polar solvent (preferably acetone or a lower alcohol) and the extract solution is then concentrated to dryness according to a conventional method to provide an anti-active oxygen action composition in an amount of <=(1/10) based on the raw material composition. Since the weight is reduced while maintaining the activity, the composition can readily be administered as a medicine and added to cosmetics and foods.
This group will receive counterstrain technique along with routine physical therapy. This protocol will be given for 3 alternative days for 2 weeks . Each session will be of 50 mins. Data will be collected at baseline , at 1st week and at 2nd week.
PURPOSE:To obtain the subject therapeutic agent capable of suppressing the hyperplasia of intravascular membrane, highly effective for treating ischemic cardiopathy, esp., highly useful for preventing the reconstriction after percutaneously coronary plasty. CONSTITUTION:This therapeutic agent contains a calponin gene as an active ingredient. Incorporation of the calponin gene into the vascular wall suppresses the proliferation of the smooth muscle cells therein. It is preferable that the calponin gene be encapsulated into a membrane of synthetic or natural origin (pref. liposome) and administered; thereby preventing this gene from being digested by nuclease and also enabling the incorporation of the gene into cells in high efficiency without damaging the cells. The calponin gene may also be such a one contained in a recombinant vector capable of manifesting this gene in smooth muscle cells, pref. a recombinant vector pCAGGS/hCN having a size of about 6.5kb shown in a restriction enzyme map in the figure.
1364672 Penicillin esters and bromophthalide BEECHAM GROUP Ltd 23 June 1972 [9 June 1971] 19604/71 Headings C2A and C2C The novel phthalidyl ester of 6 - [D(-) - α- aminophenylacetamido] penicillanic acid of Formula I: and pharmaceutically acceptable acid addition salts thereof, e.g. salts with hydrochloric acid and 3 - (2<SP>1</SP> - chloro - 6<SP>1</SP> - fluorophenyl) - 5 - methyl- 4-isoxazolyl - penicillin, may be prepared (1) by reacting 6-aminopenicillanic acid phthalide ester or a silyl derivative thereof with a reactive N-acylating derivative of the (-) isomer of a compound of Formula II: wherein X is an amino group, a protected amino group or a group which is convertible to an amino group, removing the silyl group, if present, by hydrolysis or alcoholysis, and if X is not an amino group, converting it to such a group under neutral or acid conditions or (2) by reacting a compound of Formula V: or a reactive esterifying derivative thereof, in which X is as above defined, with a compound of Formula VI: or a reactive esterifying derivative thereof, and, if X is not an amino group, subsequently converting it to an amino group under neutral or acid conditions. The novel 6-aminopenicillanic acid phthalidyl ester may be prepared by coupling 6-aminopenicillanic acid with 3-bromophthalide or by coupling an N-protected derivative of 6-aminopenicillanic acid with 3-bromophthalide and thereafter removing the protecting group. The phthalidyl esters of 6-[D(-)α-aminophenylacetamido] penicillanic acid having an N- protected amino group or a group convertible to an amino group are also stated to be novel. 3-Bromo-phthalide is prepared by reacting phthalide with N-bromosuccinimide. Pharmaceutical compositions comprise the phthalidyl ester of 6-[D(-)α-aminophenylacetamido] penicillanic acid or a pharmaceutically acceptable acid addition salt thereof and a carrier. The compositions may be administered orally in the form of powders, syrups, tablets, capsules or pills.
This is an open-label (all people know the identity of the intervention), multicenter (study conducted at multiple sites), dose escalation study. The study consists of 3 phases, including, the screening phase (within 14 days prior to the first study medication), the treatment phase, and the follow up phase. In the treatment phase, patients with recurrent mature B-cell neoplasms will be divided into 2 cohorts: Cohort 1 (consisting of between 3 and 12 patients), and Cohort 2 (consisting of between 6 and 12 patients). Cohort 1 will be further divided into 2 phases: a single dose (SD) phase and a multiple dose (MD) phase. During the initial SD phase, patients will first receive a single dose of PCI-32765 at 140 mg. After a washout period (period when the participant is not receiving any study medication) of between 72 and 168 hours, patients will then receive a second single dose of PCI-32765 at 280 mg. Following a second washout period, patients will enter the MD phase, where they will receive PCI-32765 at multiple doses of 420 mg per day for 35 days during the first cycle (35 days in Cycle 1) and for 28 days during the second cycle (28 days in Cycle 2) and every cycle thereafter. In cohort 2, patients will receive multiple doses of 560 mg per day for 35 days in Cycle 1, 28 days in Cycle 2, and every cycle thereafter. The patient's registration in Cohort 2 will be started after tolerability of Cohort 1 is confirmed. Tolerability of each dose level will be evaluated based on the dose-limiting toxicity (DLT) occurrence rate in Cycle 1 of each Cohort. Following the tolerability of the 420 mg/day dose level in subjects with mature B-cell neoplasms is confirmed in Cohort 1, a CLL/SLL Cohort will be added to further evaluate the safety and tolerability of this dose in this specific population in Japanese since 420 mg/day is the globally recommended dose for subjects with CLL and SLL, which are specific disease entities within mature B-cell neoplasms. Between 6 and 12 subjects will be enrolled in the CLL/SLL Cohort and will receive continuous dosing of PCI-32765 at 420 mg/day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. Safety evaluations for adverse events, clinical laboratory tests, electrocardiogram, vital signs, Eastern Cooperative Oncology Group (ECOG) performance status, physical examination, and corneal eye examination will be monitored throughout the study.
Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
The invention relates to a hair product. The hair product consists of a leave-in aerated cleanser that at least partially sheathes at least one hair shaft, the cleanser simultaneously and synergistically absorbing sebum from the surface of the hair shaft and providing a volumising effect and an applicator for applying the cleanser to the hair. The leave in aerated cleanser is a protein-based cleanser and more specifically an albumin cleanser. The albumin utilised in the manufacture of the hair product is typically egg-white derived albumin. In addition to the cleansing effect exhibited by the hair product the aerated cleanser, once applied to the at least one hair shaft, also functions to shield keratin fibres in the at least one hair shaft from external damage which may be caused by heat or by exposure to the elements. Furthermore, the hair product also imparts a conditioning effect to the hair shaft surface. The hair product may contain at least one additional agent. The additional agent being selected from the group including: preservative agents, cosmetic agents, fragrance agents, medicaments, conditioning agents, moisturizing agents and colouring agents.